Shares of the company are trading at $2.25 which is well above $1.94, the stock’s 50 day moving average and quite a bit higher than the 200 day moving average of $1.52. The 50 day moving average was up $0.31 or +15.85% whereas the 200 day moving average was up $0.73 or +48.17%. Trading was light with 615 shares changing hands on Tuesday. Volume was down 99.52% under the stocks average daily volume.
Investors are more bullish on the company lately considering the fall in short interest. The company experienced a fall in short interest between September 15, 2017 and September 29, 2017 of -13.23%. Short interest fell 9,098 over that timeframe. Days to cover decreased -1.0 to 0.0 and the short interest percentage is 0.00% as of September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (PRTO). As of the end of the quarter Mariner Wealth Advisors, LLC had disposed of 1,125 shares trimming its holdings by 10.1%. The value of the investment in Proteon Therapeutics, Inc. decreased from $19,000 to $15,000 a change of $4,000 quarter to quarter. As of quarter end Tower Research Capital LLC (trc) had sold a total of 3,115 shares trimming its position 53.8%. The value of the investment in PRTO went from $10,000 to $4,000 decreasing 60.0% for the reporting period.
Kcg Holdings, Inc. cut its position by shedding 23,742 shares a decrease of 64.8% in the quarter. Kcg Holdings, Inc. now controls 12,924 shares valued at $20,000. The total value of its holdings decreased 68.8%. Acadian Asset Management LLC trimmed its ownership by selling 1,500 shares a decrease of 17.7% from 06/30/2017 to 09/30/2017. Acadian Asset Management LLC owns 6,990 shares worth $14,000. The value of the position overall is up by 7.7%.
As of the last earnings report the EPS was $-1.56 and is projected to be $-1.52 for the current year with 17,619,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.41 and the next full year EPS is anticipated to be $-1.54.
Proteon Therapeutics, Inc., launched on March 24, 2006, is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Business’s product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). It initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs..